Moderna's mFlusiva: First mRNA flu vaccine approved for seniors

Moderna's mFlusiva vaccine, approved for people aged 50 and older in the U.S., shows stronger, longer-lasting flu protection than standard shots in clinical trials.

The U.S. Food and Drug Administration approved Moderna’s mFlusiva for individuals aged 50 and older on August 5, 2026. This mRNA-based vaccine—identical in technology to COVID-19 vaccines—reduced flu cases by 27 percent compared to conventional flu vaccines in a trial of 40,000 participants. It generated higher antibody levels that persisted for six months post-vaccination, outperforming standard flu vaccines that typically show 40–60 percent effectiveness annually. The vaccine is now available at select drug stores for seniors ahead of the upcoming flu season.

The clinical trial data, published in *Nature Immunology* on June 15, 2026, demonstrates mFlusiva’s superior immune response in older adults. This matters for flu season because the elderly face higher risks from seasonal influenza, and the vaccine’s extended protection could reduce hospitalizations and healthcare strain. However, effectiveness in younger populations remains unverified, and the 27 percent reduction represents a relative comparison—absolute case numbers are not specified.

For abundance, this means more reliable flu protection for a vulnerable group without increasing healthcare costs during peak seasons. What to watch: Moderna’s path to approval for under-50s and whether broader transmission reduction occurs beyond immune response. The source notes that conventional flu vaccine effectiveness varies yearly due to strain mismatches, and the study’s focus on older adults means real-world impact on community spread requires further research.

Source: Science News